Kura Oncology, Inc.

NasdaqGS:KURA 주식 보고서

시가총액: US$1.6b

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Kura Oncology 관리

관리 기준 확인 4/4

Kura Oncology's CEO는 Troy Wilson, Mar2015 에 임명되었습니다 의 임기는 9.25 년입니다. 총 연간 보상은 $ 5.25M, 12.3% 로 구성됩니다. 12.3% 급여 및 87.7% 보너스(회사 주식 및 옵션 포함). 는 $ 11.46M 가치에 해당하는 회사 주식의 0.76% 직접 소유합니다. 11.46M. 경영진과 이사회의 평균 재임 기간은 각각 3.5 년과 8.7 년입니다.

주요 정보

Troy Wilson

최고 경영자

US$5.3m

총 보상

CEO 급여 비율12.3%
CEO 임기9.3yrs
CEO 소유권0.8%
경영진 평균 재임 기간3.5yrs
이사회 평균 재임 기간8.7yrs

최근 관리 업데이트

Recent updates

Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

May 08
Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

Kura Oncology: Balancing Act Of Promise And Pragmatism

May 07

Kura Oncology: Ziftomenib's Path To AML Market Widens

Jan 31

Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price

Jan 25
Kura Oncology, Inc.'s (NASDAQ:KURA) Intrinsic Value Is Potentially 72% Above Its Share Price

Is Kura Oncology (NASDAQ:KURA) A Risky Investment?

Aug 14
Is Kura Oncology (NASDAQ:KURA) A Risky Investment?

Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

Apr 04
Is Kura Oncology (NASDAQ:KURA) Using Debt Sensibly?

Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?

Jan 31
Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 44% Undervaluation?

Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans

Oct 10
Kura Oncology (NASDAQ:KURA) Is In A Good Position To Deliver On Growth Plans

Kura Oncology stock rises 7% as Cantor Fitzgerald begins coverage with Overweight rating

Jul 13

We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth

Jun 26
We Think Kura Oncology (NASDAQ:KURA) Can Afford To Drive Business Growth

We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Nov 23
We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Aug 09
We're Not Very Worried About Kura Oncology's (NASDAQ:KURA) Cash Burn Rate

Kura Oncology Investor Presentation - Slideshow

May 08

What Kind Of Shareholders Hold The Majority In Kura Oncology, Inc.'s (NASDAQ:KURA) Shares?

Dec 14
What Kind Of Shareholders Hold The Majority In Kura Oncology, Inc.'s (NASDAQ:KURA) Shares?

Kura Oncology: Advanced Precision Medicine Opportunity Excites, But Not Without Risks

Dec 10

Kura Oncology (KURA) Presents At ASH Virtual Investor Event

Dec 08

Kura Oncology Jumps 16% After Announcing First In-Human Data for AML Candidate

Dec 07

Kura Oncology (KURA) Presents At Stifel Healthcare Conference - Slideshow

Nov 17

CEO 보상 분석

Troy Wilson 의 보수는 Kura Oncology 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$168m

Dec 31 2023US$5mUS$646k

-US$153m

Sep 30 2023n/an/a

-US$143m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$137m

Dec 31 2022US$5mUS$621k

-US$136m

Sep 30 2022n/an/a

-US$135m

Jun 30 2022n/an/a

-US$133m

Mar 31 2022n/an/a

-US$132m

Dec 31 2021US$9mUS$600k

-US$130m

Sep 30 2021n/an/a

-US$124m

Jun 30 2021n/an/a

-US$114m

Mar 31 2021n/an/a

-US$101m

Dec 31 2020US$4mUS$573k

-US$90m

Sep 30 2020n/an/a

-US$81m

Jun 30 2020n/an/a

-US$74m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$3mUS$542k

-US$63m

Sep 30 2019n/an/a

-US$61m

Jun 30 2019n/an/a

-US$60m

Mar 31 2019n/an/a

-US$60m

Dec 31 2018US$5mUS$526k

-US$60m

Sep 30 2018n/an/a

-US$55m

Jun 30 2018n/an/a

-US$49m

Mar 31 2018n/an/a

-US$43m

Dec 31 2017US$2mUS$472k

-US$35m

보상 대 시장: Troy 의 총 보상 ($USD 5.25M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 5.67M ).

보상과 수익: Troy 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Troy Wilson (55 yo)

9.3yrs

테뉴어

US$5,251,407

보상

Dr. Troy Edward Wilson, Ph D., J.D., is Co-Founder of Avidity Biosciences Inc. and had been its Executive Chairman since February 2019 until January 2021 and serves as its Independent Chairman of the Board...

리더십 팀

이름위치테뉴어보상소유권
Troy Wilson
Chairman9.3yrsUS$5.25m0.76%
$ 11.9m
Kathleen Ford
Chief Operating Officer4.8yrsUS$2.16m0.014%
$ 218.3k
Teresa Bair
Chief Legal Officer & Corporate Secretary2.7yrsUS$1.98m0.0071%
$ 110.4k
Stephen Dale
Chief Medical Officer3.8yrsUS$2.47m0.0040%
$ 62.0k
Thomas Doyle
Senior Vice President of Finance & Accounting2.3yrs데이터 없음0.016%
$ 243.5k
Pete De Spain
Executive Vice President of Investor Relations & Corporate Communications6.7yrs데이터 없음데이터 없음
Roger Bakale
Senior Vice President of Manufacturing & Supply Chain4.4yrs데이터 없음데이터 없음
Maureen Clancy
VP and Global Head of Program Leadership & Project Management3.3yrs데이터 없음데이터 없음
Mollie Leoni
Executive Vice President of Clinical Development2.3yrs데이터 없음데이터 없음
Brian Powl
Chief Commercial Officerless than a year데이터 없음데이터 없음
Francis Burrows
Senior Vice President of Translational Researchno data데이터 없음데이터 없음

3.5yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: KURA 의 관리팀은 경험 ( 3.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Troy Wilson
Chairman9.3yrsUS$5.25m0.76%
$ 11.9m
Daniel Von Hoff
Clinical Advisorno data데이터 없음데이터 없음
Thomas Malley
Independent Director8.7yrsUS$275.69k0%
$ 0
Mary Szela
Independent Director5.6yrsUS$279.80k0%
$ 0
Faheem Hasnain
Lead Independent Director9.2yrsUS$300.54k0.031%
$ 491.6k
Frank McCormick
Scientific Advisorno data데이터 없음데이터 없음
Neal Rosen
Scientific Advisorno data데이터 없음데이터 없음
Kevan Shokat
Chairman of the Scientific Advisory Boardno data데이터 없음데이터 없음
Alan Houghton
Clinical Advisorno data데이터 없음데이터 없음
Josep Tabernero
Clinical Advisorno data데이터 없음데이터 없음
Steven Horwitz
Clinical Advisorno data데이터 없음데이터 없음
Carol Schafer
Independent Director3yrsUS$279.05k0%
$ 0

8.7yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: KURA 의 이사회는 경험(평균 재직 기간 8.7 년)으로 간주됩니다.